Sentences with phrase «in disease development»

Furthermore the identification of genes implied in disease development will allow to understand the mechanisms and pathways of the pathology.

With an autosomal dominant disease, if one of the pair of genes is abnormal, this is «dominant» over the normal gene, and results in disease development.

Cheryl - Without going into too much detail, the first of the crucial defining moments in my disease development may have started during my undergraduate studies at the University of Illinois.

Janet - Without going into too much detail, the first of the crucial defining moments in my disease development may have started during my undergraduate studies at the University of Illinois.

Maureen - Without going into too much detail, the first of the crucial defining moments in my disease development may have started during my undergraduate studies at the University of Illinois.

Cara - Without going into too much detail, the first of the crucial defining moments in my disease development may have started during my undergraduate studies at the University of Illinois.

Eric - Without going into too much detail, the first of the crucial defining moments in my disease development may have started during my undergraduate studies at the University of Illinois.

Patty - Without going into too much detail, the first of the crucial defining moments in my disease development may have started during my undergraduate studies at the University of Illinois.

Mary - Without going into too much detail, the first of the crucial defining moments in my disease development may have started during my undergraduate studies at the University of Illinois.

Anne - Without going into too much detail, the first of the crucial defining moments in my disease development may have started during my undergraduate studies at the University of Illinois.

«These enzymes have also become increasingly important in disease development, particularly cancer, and efforts have intensified to develop specific pharmacological inhibitors targeting them.»

Impaired mitochondrial function and structure in motor neurons were discovered before symptoms occurred, suggesting a role in disease development.

The team found that most of the genetic changes in the original breast tumour were also present in the metastatic tumours, showing that the cancer cells spread late in disease development.

«The mitochondrial and lysosomal pathways are two critical pathways in disease development,» said Krainc, who also is the director of the Center for Rare Neurological Diseases and a professor of neurological surgery and of physiology.

This study was designed to better define the process by which ALS progresses and to explore the role of brain motor neurons in disease development and progression.

Not exact matches

Important factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost of accommodating, announced increases in the build rates of certain aircraft; 6) the effect on aircraft demand and build rates of changing customer preferences for business aircraft, including the effect of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution of key milestones such as the receipt of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or other third party approvals for the consummation of our announced acquisition of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect of changes in tax law, such as the effect of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability of raw materials and purchased components; 23) our ability to recruit and retain a critical mass of highly - skilled employees and our relationships with the unions representing many of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment of interest on, and principal of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness of any interest rate hedging programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks of doing business internationally, including fluctuations in foreign current exchange rates, impositions of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.

Founded in 2011, Innovent has built a portfolio of 16 potential products for treating cancer, autoimmune disorders and other diseases, and seven of those are in clinical development.

«Expanding our collaboration with Banner Alzheimer's Institute stands testament to our belief that preventing amyloid buildup is one of the most promising approaches to treating Alzheimer's disease,» said Novartis» chief medical officer, global head of drug development, and soon - to - be CEO Dr. Vas Narasimhan in a statement.

Striking advances in hepatitis C drug development over the past five years have made the infectious, liver - wasting viral disease a curable one — if you can afford the drugs.

Perhaps no field in the life sciences has been as heartbreaking, from a drug development standpoint, as Alzheimer's disease and dementia.

Brian Cheng, executive director at NWS Holdings, said: «We believe Medopad will succeed in revolutionizing the current convoluted methods of disease treatment and prevention into a more succinct ecosystem with the development of its artificial intelligence and big data gathering capabilities.»

Acceleron focuses its research and development efforts in hematologic, neuromuscular, and pulmonary diseases.

• Excision BioTherapeutics, a Philadelphia - based life science company focused on the development and commercialization of advanced gene editing therapeutics for the treatment of life - threatening disease caused by neurotropic viruses, raised $ 10 million in seed funding.

Amgen Executive Vice President of Research and Development Sean Harper said the study was designed to explore Kyprolis dosing regimens, noting that the the trial did not meet its goal in improving progression - free survival versus Velcade in patients who had not yet been treated for the disease.

Stoke Therapeutics Expands Leadership Team, Building on Deep Expertise in Oligonucleotide Chemistry and Rare Disease Research and Development

GSK has 15 vaccine candidates in development against diseases, including shingles, RSV, GBS, and chronic obstructive pulmonary disease (COPD) exacerbations.

The company is also seeking deeper inroads into rare diseases, with a number of assets in late - stage development, and last year it scored a major regulatory win when Europe approved its «bubble boy syndrome» gene therapy Strimvelis.

Mannkind, which focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, entered a shallow but persistent downtrend in 2004, posting a series of lower highs into 2015.

The rising incidence of diseases like Alzheimer's and autism coupled with developments in artificial intelligence and machine...

At Ionis Pharmaceuticals, we are dedicated to the discovery and development of novel, first - in - class or best - in - class antisense drugs to address significant unmet medical needs in a wide variety of diseases.

We are bringing together fiscal policy, development, and health leaders from around the globe, including Ministers of Finance, to address the enormous and growing health and economic burden of non-communicable diseases (NCDs) in lower and middle income countries (LMICs).

Minoryx is a drug development company specializing in the discovery of new drugs for orphan diseases.

Mataró, Barcelona, Spain — October 14, 2015 — Minoryx Therapeutics, a drug development company specialized in the discovery of new drugs for orphan diseases, today announces it has completed a Series A funding round of $ 19.4 M ($ 21.7 M).

Cambridge, MA — March 30, 2017 — Aura Biosciences, a biotechnology company developing a new class of therapies to target and selectively destroy cancer cells using viral nanoparticle conjugates, announced today that it has enrolled and dosed the first patient in its Phase 1b clinical trial of light - activated AU - 011, an investigational, first - in - class targeted therapy in development for the treatment of ocular melanoma, a rare and life - threatening disease.

It is a differentiated PPAR gamma agonist with a superior profile for CNS related diseases with excellent in - vivo efficacy, a comprehensive development plan and early involvement from key opinion leaders.

Experience in orphan disease drug development and an understanding of genetic concepts and molecular biology laboratory techniques is beneficial.

To achieve this goal, several approaches are envisaged: identifying small populations with severe disease where a medicine's benefit - risk balance could be favorable; making more use of real - world data where appropriate to support clinical trial data; and involving health technology assessment bodies early in development to increase the chance that medicines will be recommended for payment and ultimately covered by national healthcare systems.

The company's lead product candidate is amikacin liposome inhalation suspension, which is in late - state development for adult patients with treatment refractory nontuberculous mycobacteria lung disease caused by mycobacterium avium complex.

There are currently 176 biologics in development to treat infectious diseases alone.

That therapy for treating melanoma is already in the development pipeline, along with 906 other biologics targeting over 100 diseases from autoimmune disorders to viruses.

Health care companies have also continued to expand their research and development efforts, resulting in innovative discoveries as well as cures and treatments for many diseases.

In this first article, a summary is given of how and where the banana export trades began, the early history of Panama disease, and the important effect that the disease had on the development of this industry.

In 1999, we are no longer reduced to «guessing» whether he was inspired or speaking only as a man: • adultery has lost its moral significance and become commonplace; • chastity has become a symbol of unhealthy development; • contraception in expectation of fornication is taught to children in the schools; • respect between the sexes has been replaced by mutual exploitation and / or competition; • marriage has lost its sacramental nature and its enduring promise; • statistically, divorce is common, teenage pregnancy is widespread, single parent and serially parented families increase, sexual disease is epidemic, intercourse is recreational, abortion is ubiquitouIn 1999, we are no longer reduced to «guessing» whether he was inspired or speaking only as a man: • adultery has lost its moral significance and become commonplace; • chastity has become a symbol of unhealthy development; • contraception in expectation of fornication is taught to children in the schools; • respect between the sexes has been replaced by mutual exploitation and / or competition; • marriage has lost its sacramental nature and its enduring promise; • statistically, divorce is common, teenage pregnancy is widespread, single parent and serially parented families increase, sexual disease is epidemic, intercourse is recreational, abortion is ubiquitouin expectation of fornication is taught to children in the schools; • respect between the sexes has been replaced by mutual exploitation and / or competition; • marriage has lost its sacramental nature and its enduring promise; • statistically, divorce is common, teenage pregnancy is widespread, single parent and serially parented families increase, sexual disease is epidemic, intercourse is recreational, abortion is ubiquitouin the schools; • respect between the sexes has been replaced by mutual exploitation and / or competition; • marriage has lost its sacramental nature and its enduring promise; • statistically, divorce is common, teenage pregnancy is widespread, single parent and serially parented families increase, sexual disease is epidemic, intercourse is recreational, abortion is ubiquitous.

In the light of man's unrelenting attack on disease, some biologists believe that development of deadly germs is a betrayal of the human race as well as of the ideals of science; one - hundredth of an ounce of botulism toxin could kill a million people, and its production seems to further neither scientific knowledge nor any peacetime applications.

Such embryo research might teach us more about cell differentiation and early embryo development, it might make possible greater success in bone marrow transplants, and it might help us to treat more successfully degenerative diseases and spinal cord injuries.

About five percent are used for teaching purposes, another five percent for diagnosis of disease, twenty percent for production of biological substances («biologicals») and for toxicity testing, thirty percent in development of drugs and their testing, and forty percent for other research activities such as the present work in genetic engineering to increase the size of sheep and pigs.

There is barely a passing mention of thousands of nongovernmental programs, mainly church - related, that are demonstrably effective in countering disease, feeding the hungry, and advancing development by building communities of mutual aid.

Cholesterol and saturated fat in food have the ability to raise blood cholesterol levels, which can lead to the development of heart disease.

According to the University of Maryland Medical Center polyunsaturated fatty acids (PUFAs)-- also known as omega - 3 fatty acids — play a crucial role in human brain function, as well as normal growth and development, with research showing that they can also reduce inflammation in addition to helping lower the risk of chronic diseases such as heart disease, cancer, and arthritis.

Now, coconut milk is high in saturated fat, long thought to be a main factor in the development of obesity and heart / brain disease.